MiRNA expression patterns predict survival in glioblastoma

[1]  E. Shaw,et al.  Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. , 2011, International journal of radiation oncology, biology, physics.

[2]  J. Tonn,et al.  FET-PET for malignant glioma treatment planning. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  Claus Belka,et al.  MicroRNA expression profiles in human cancer cells after ionizing radiation , 2011, Radiation oncology.

[4]  Li-Hsin Chen,et al.  Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response , 2011, Radiation oncology.

[5]  P. Gutin,et al.  Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches , 2011, Radiation oncology.

[6]  E. Chiocca,et al.  Potential role of miRNAs and their inhibitors in glioma treatment , 2010, Expert review of anticancer therapy.

[7]  Keiji Suzuki,et al.  miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. , 2010, Cancer letters.

[8]  J. Zempleni,et al.  Biotin regulates the expression of holocarboxylase synthetase in the miR-539 pathway in HEK-293 cells. , 2010, The Journal of nutrition.

[9]  Jun Li,et al.  Biomarkers , Genomics , Proteomics , and Gene Regulation miR-182 as a Prognostic Marker for Glioma Progression and Patient Survival , 2010 .

[10]  A. Gulino,et al.  MicroRNAs as biomarkers for CNS cancer and other disorders , 2010, Brain Research.

[11]  Alessia Pica,et al.  Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Kai Stühler,et al.  Identification and Functional Characterization of microRNAs Involved in the Malignant Progression of Gliomas , 2010, Brain pathology.

[13]  Wei Zhu,et al.  MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. , 2010, Oncology reports.

[14]  J. Welsh,et al.  The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells , 2009, Radiation oncology.

[15]  O. Ratib,et al.  Recurrence pattern after [(18)F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  Zheng Chang,et al.  ExacTrac X-ray 6 degree-of-freedom image-guidance for intracranial non-invasive stereotactic radiotherapy: comparison with kilo-voltage cone-beam CT. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  G. Stoffels,et al.  Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme - a dosimetric comparison , 2009, Radiation oncology.

[18]  P. Cao,et al.  Let-7a microRNA functions as a potential tumor suppressor in human laryngeal cancer. , 2009, Oncology reports.

[19]  J. Mehrkens,et al.  Novel Molecular Stereotactic Biopsy Procedures Reveal Intratumoral Homogeneity of Loss of Heterozygosity of 1p/19q and TP53 Mutations in World Health Organization Grade II Gliomas , 2009, Journal of neuropathology and experimental neurology.

[20]  K. Camphausen,et al.  A dosimetric comparison of four treatment planning methods for high grade glioma , 2009, Radiation oncology.

[21]  J. Hodgson,et al.  microRNAs in Gliomas: Small Regulators of a Big Problem , 2009, NeuroMolecular Medicine.

[22]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Jenghwa Chang,et al.  Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. , 2009, International journal of radiation oncology, biology, physics.

[24]  Jana Novakova,et al.  MicroRNA involvement in glioblastoma pathogenesis. , 2009, Biochemical and biophysical research communications.

[25]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[26]  L. Gaspar,et al.  Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas. , 2009, International journal of radiation oncology, biology, physics.

[27]  M. Campone,et al.  Facteurs pronostiques et prédictifs de réponse des gliomes cérébraux de l’adulte , 2009 .

[28]  Tithi Biswas,et al.  Stereotactic radiosurgery for glioblastoma: retrospective analysis , 2009, Radiation oncology.

[29]  Francesco Tomasello,et al.  miR-21 and 221 upregulation and miR-181b downregulation in human grade II–IV astrocytic tumors , 2009, Journal of Neuro-Oncology.

[30]  Habib Zaidi,et al.  [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma , 2008, Radiation oncology.

[31]  Anna M. Krichevsky,et al.  miR-21: a small multi-faceted RNA , 2008, Journal of cellular and molecular medicine.

[32]  Holly Ning,et al.  Comparison of T2 and FLAIR imaging for target delineation in high grade gliomas , 2008, Radiation oncology.

[33]  J. Herman,et al.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  G. Reifenberger,et al.  Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas , 2007, International journal of cancer.

[35]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[36]  R. Stupp,et al.  MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma? , 2007, Disease markers.

[37]  G. Maira,et al.  Extensive modulation of a set of microRNAs in primary glioblastoma. , 2005, Biochemical and biophysical research communications.

[38]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[39]  H. Meijer,et al.  Mechanisms of translational control by the 3' UTR in development and differentiation. , 2005, Seminars in cell & developmental biology.

[40]  F. Davis,et al.  Epidemiology of brain tumors. , 2000, Current opinion in neurology.

[41]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[42]  J. Tonn,et al.  Irradiation and bevacizumab in high-grade glioma retreatment settings. , 2012, International journal of radiation oncology, biology, physics.

[43]  J. Tonn,et al.  Therapeutic options for recurrent malignant glioma. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[44]  H. Armah.  Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas , 2010 .

[45]  M. Campone,et al.  [Prognostic and predictive factors for gliomas in adults]. , 2009, Bulletin du cancer.

[46]  M. Wolter,et al.  MicroRNA: Biogenesis, Regulation, and Role in Primary Brain Tumors , 2009 .

[47]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[48]  J. Barciszewski,et al.  Therapeutic Ribonucleic Acids in Brain Tumors , 2009 .